LANSING, Mich., May 12, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) announce that the scientific team is preparing to significantly ramp up the number of genetic insertions performed in the month of May. The team anticipates that the rate of DNA construct insertions in May will be double that which has been performed to date.

“We are now entering the next phase in which the team is reallocating recourses to genetic insertion,” said CEO Kim Thompson.

“This is directly related to our recent development of new DNA constructs that are specifically targeted for the production of new fusion silk proteins. We intend to dramatically ramp up the number of insertions performed in order to gain the maximum benefit from the new insertion packets.”

Every targeted DNA packet insertion has the potential to create a new recombinant fiber with commercial applications.

Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company plans to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.

For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking

statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

LANSING, Mich., May 4, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) is pleased to announce that Dr. Malcolm Fraser, working in cooperation with Dr. Wang, Dr. Sohn and other members of the scientific team have recently succeeded in building eight unique DNA constructs which the team is preparing for genetic insertion over the next several weeks. These genetic insertion packets include several that are specifically targeted for the production of new fusion silk proteins.

“These constructs include a number of new DNA combinations that are truly exciting,” said CEO Kim K. Thompson. “The increases in laboratory productivity over the last eight months are now enabling us to do more and to do it faster. This number of unique genetic constructs is a new breakthrough for the Company. Each of these constructs has the potential to result in the development of a new polymer or high performance fiber.” The genetic constructs are customized packets of DNA which provide genetic instructions for the creation of new polymers and spider silk based proteins.

Over the last year, the University of Notre Dame added of Dr. Wang, Dr. Sohn and other scientists to the research team. “Since that time we have seen a dramatic increase in both the quality and quantity of the work performed,” said Thompson. “We are ready to ramp up our effort to insert as many constructs as possible,” added Dr. Fraser.

Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company plans to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.

For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

LANSING, Mich., April 27, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) confirms that the record date for the stock dividend is today, April 27, 2009. The press release of April 23^rd contained a typographical error and mistakenly referred to April 27^th as the Ex Date. Stock holders are instructed to disregard the April 27 press release.

The ex date is currently set as May 28, 2009. Please use the following link to see

NASDAQ Group’s posting:

http://www.otcbb.com/asp/dividend.asp?sym_id=KBLB&dDate=4/27/2009&sDateType=Record_date

We can not provide trading advice. Please consult with your broker regarding the stock distribution. Stock holders who sell their stock today or before the ex date may be selling the right to the distribution. Please consult with your broker.

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

LANSING, Mich., April 15, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) has declared a stock dividend. All shareholders of record as of the close of business on the record date will be issued nine additional shares for each share of common stock held. The record date is April 27, 2009.

“This stock dividend is intended to lay the groundwork for the growth of the Company,” said CEO Kim K. Thompson. “It is part of our ongoing efforts to promote capital investment, broaden ownership, improve trading liquidity, and enhance shareholder value. This action is enabled by the Company’s continued success in the laboratory and is consistent with the Board’s commitment to take actions designed to increase capital investment and create a wider distribution of the Company’s stock.”

The declaration of the stock dividend follows the announcement over the last several months of significant increases in laboratory productivity. The Company believes these dramatic increases in productivity are the direct result of the Company’s successful efforts to recruit highly talented scientists and researchers in 2008. “Ultimate credit for the increased pace of work in the laboratory belongs to Dr. Fraser and the University of Notre Dame research team,” said Kim Thompson.

Kraig is a biotechnology company developing advanced materials and high performance polymers. The Company believes that these materials have the potential to make a significant impact on the $92 billion market for high performance and technical fibers. The Company works in cooperation with leading universities and university researchers, and virtually all of the scientific research is conducted within university laboratories. For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

LANSING, Mich., March 30, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) is very pleased to report that scientists working in the Company’s sponsored research program at the University of Notre Dame have succeeded in significantly increasing the number and proportion of DNA insertions which yield transient expression of the Company’s targeted marker protein. “These results, which are occurring in the latest generation of genetic insertions performed in the laboratory, are very exciting, and we believe that it is further evidence that research team is on the right track” said CEO Kim K. Thompson.

The increase which the team is reporting is in both absolute numbers and in the percentage of insertions which ultimately result in the expression. This progress report from the laboratory follows the Company’s announcement of the achievement of a number of milestones over the last six months. “This is the first time we have seen the number of DNA insertions yielding transient expression reach the triple digits. We do seem to be in a state of acceleration in terms of the pace of laboratory achievement,” added Mr. Thompson.

For more information on Kraig Biocraft Laboratories, please visit the Company’s web site: www.KraigLabs.com

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops”, “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT:

Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

EAST LANSING, Mich., March 24, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) today announced that its Board of Directors has approved a stock dividend. The Board declared that shareholders of record as of the close of business on the record date will be issued nine additional shares for each share of Common Stock held.

“This stock dividend is intended to lay the groundwork for the growth of the Company,” said CEO Kim K. Thompson. “It is part of our ongoing efforts to improve trading liquidity, broaden ownership, promote capital investment and enhance shareholder value. This action is enabled by the Company’s continued success in the laboratory and is consistent with the Board’s commitment to take actions designed to create a wider distribution of the Company’s stock.”

The Board has directed the Company’s officers to confer with market oversight authorities and its transfer agents as soon as is practical to determine a record date.

Kraig is a biotechnology company working to develop and commercialize high performance polymers using spider silk gene sequences. The company hopes to tap into the $92 billion market for high performance and technical fibers. The Company works in cooperation with leading universities and university researchers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of genetic research within the University.

For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

EAST LANSING, Mich., March 23, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) is pleased to announce that Dr. Fraser reported this week that his team has “made significant progress on developing enzymes and strategies for conducting site specific genetic recombination in silkworm.”

“In the Company’s view, the development of this particular gene splicing technology is the key to unlocking the tremendous commercial potential of spider silks and other recombinant polymers,” said Kraig’s CEO, Kim K. Thompson. “Dr. Fraser’s report of this news from the laboratory is the culmination of years of scientific effort. It is a huge milestone on the path to commercialization,” continued Thompson.

“We believe that we are the only people who have this capability at this time.” Dr. Fraser emphasized.

Dr. Fraser’s team of research scientists, working within University of Notre Dame laboratories, has reported a number of significant advancements over the last four or five months. This most recent announcement follows closely on the heals of the Company’s announcement that it had achieved approximately five thousand genetic insertions, and that it had achieved the activation of fluorescent marker gene sequences which the researchers incorporated into spider silk DNA packets.

Site specific genetic recombination allows for the genetic targeting of a specific location on a specific chromosome. It is potentially critical to the Company’s work because of the strong influence of what geneticists’ refer to as “location effects.” Location effects are effects that result not from the coding of a specific gene, but from the location of that gene on a specific chromosome.

For more information on Kraig Biocraft Laboratories, please visit the Company’s web site: www.KraigLabs.com

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believe,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “seen,” “develops”, “researching,” “research,” “potential,” “path,” “progress,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

The New Record Is A Direct Result Of The Recent Reorganization Of The Notre Dame Research Team

Scientists See Increase In Transient Expression As Strong Evidence Of The Viability Of The DNA Insertions

EAST LANSING, Mich., February 10, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) is pleased to announce that Dr. Fraser’s research team recently accomplished five thousand genetic transfers in a single week using the newly designed DNA insertion packets. “Every DNA packet insertion has the potential to create a new recombinant fiber with commercial applications. The achievement of 5,000 such insertions in a single week is something that the Company would not have dreamed of in 2008,” said CEO Kim K Thompson. “At the same time,” Thompson continued, “Dr. Fraser is reporting a large increase in the team’s observation of the occurrence of transient expression shortly after the gene transfers are preformed.” Transient expression following a genetic insertion is seen by the research team as a strong indication of the viability of the genetic transfers.

The Company will have preliminary test results back on these five thousand genetic insertions in approximately 45 days. “More importantly,” added Mr. Thompson, “the research team is now performing these gene transfers in large numbers on a regular basis. That means that there will be a nearly continuous group of gene transfers being tested. Every single gene insertion has the potential to create a new commercially viable spider silk polymer. With this number of gene insertions the odds of our developing a viable polymer are increasing exponentially.”

The Company believes these dramatic increases in productivity are the direct result of Mr. Thompson’s successful efforts to reorganize the research team in 2008.

For more information on Kraig Biocraft Laboratories, please visit the Company’s web site: www.KraigLabs.com

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops”, “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

The Successful Activation of the Marker DNA in Silkworms is seen as a Key Indication that the Company’s Genetic Transfers are Working as Chromosomal Insertions as Planned. Congratulations to Dr. Malcolm Fraser, Dr. Fanghai Wang, Dr. Bong-Hee Sohn and the Notre Dame Research Team.

EAST LANSING, Mich., January 20, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) is very pleased to announce that the scientific team has succeeded in achieving the activation of fluorescent marker gene sequences which the researchers incorporated into spider silk DNA packets. The researchers successfully inserted the DNA packets into silkworms, which are now visibly exhibiting florescence.

“The fact that we are now seeing fluorescence in the modified silkworms establishes that the DNA insertion packets are working and that we have succeeded in obtaining chromosomal insertion and expression,” said CEO Kim K. Thompson. “In other words, not only are the DNA packets incorporating themselves into the silkworm chromosome as expected, the silkworms are actually producing the fluorescent proteins as they are instructed to do by the genetic coding in the spider silk insertion packets.”

The DNA packets contain the genetic instructions for the production of new spider silk based fibers and textiles. The florescent marker sequences which are included in the packets essentially instruct the silkworm to produce florescent proteins. When a silkworm produces florescent proteins the scientists know that they have succeeded in altering its DNA, because in nature, silkworms do not produce florescent proteins. The research team’s successful production of exogenous proteins in silkworm is a huge step forward for Kraig Labs. The fact that these proteins are markers establishes that the DNA packets, which include spider silk gene sequences, have been successfully transferred. “The atmosphere here is one of tremendous excitement,” said Thompson.

“Another generation will be required in order to test whether we have achieved a germ line stable transgenic,” continued Mr. Thompson. The team will be able to test the next generation for the florescent makers within the ten days. From then on, we should have a new generation of silkworms ready for testing at regular intervals of approximately fourteen days. This is a dramatic shift forward in the Company’s spider silk and high performance polymer development program.

For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site: www.KraigLabs.com

Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops”, “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com